These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37146250)

  • 1. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
    Khalsa JK; Cha J; Utro F; Naeem A; Murali I; Kuang Y; Vasquez K; Li L; Tyekucheva S; Fernandes SM; Veronese L; Guieze R; Sasi BK; Wang Z; Machado JH; Bai H; Alasfour M; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Paweletz CP; Leshchiner I; Parida L; Getz G; Brown JR
    Blood; 2023 Aug; 142(5):421-433. PubMed ID: 37146250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of
    Kotmayer L; László T; Mikala G; Kiss R; Lévay L; Hegyi LL; Gróf S; Nagy T; Barna G; Farkas P; Weisinger J; Nagy Z; Balogh A; Masszi T; Demeter J; Sulák A; Kohl Z; Alizadeh H; Egyed M; Pettendi P; Gergely L; Plander M; Pauker Z; Masszi A; Matolcsy A; Szász R; Bödör C; Alpár D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
    Thomalla D; Beckmann L; Grimm C; Oliverio M; Meder L; Herling CD; Nieper P; Feldmann T; Merkel O; Lorsy E; da Palma Guerreiro A; von Jan J; Kisis I; Wasserburger E; Claasen J; Faitschuk-Meyer E; Altmüller J; Nürnberg P; Yang TP; Lienhard M; Herwig R; Kreuzer KA; Pallasch CP; Büttner R; Schäfer SC; Hartley J; Abken H; Peifer M; Kashkar H; Knittel G; Eichhorst B; Ullrich RT; Herling M; Reinhardt HC; Hallek M; Schweiger MR; Frenzel LP
    Blood; 2022 Nov; 140(20):2113-2126. PubMed ID: 35704690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
    Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
    Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
    Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
    Chong SJF; Zhu F; Dashevsky O; Mizuno R; Lai JX; Hackett L; Ryan CE; Collins MC; Iorgulescu JB; Guièze R; Penailillo J; Carrasco R; Hwang YC; Muñoz DP; Bouhaddou M; Lim YC; Wu CJ; Allan JN; Furman RR; Goh BC; Pervaiz S; Coppé JP; Mitsiades CS; Davids MS
    J Clin Invest; 2023 Nov; 133(22):. PubMed ID: 37751299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.
    Thijssen R; Tian L; Anderson MA; Flensburg C; Jarratt A; Garnham AL; Jabbari JS; Peng H; Lew TE; Teh CE; Gouil Q; Georgiou A; Tan T; Djajawi TM; Tam CS; Seymour JF; Blombery P; Gray DHD; Majewski IJ; Ritchie ME; Roberts AW; Huang DCS
    Blood; 2022 Nov; 140(20):2127-2141. PubMed ID: 35709339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
    Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
    Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
    Bennett R; Thompson E; Tam C
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
    Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
    Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
    Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
    Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
    Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
    Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
    Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
    Ahn IE; Davids MS
    Semin Hematol; 2024 Apr; 61(2):109-118. PubMed ID: 38538512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax resistance and acquired
    Tausch E; Close W; Dolnik A; Bloehdorn J; Chyla B; Bullinger L; Döhner H; Mertens D; Stilgenbauer S
    Haematologica; 2019 Sep; 104(9):e434-e437. PubMed ID: 31004028
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax in the treatment of chronic lymphocytic leukemia.
    Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
    Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
    Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.